Cross-protection of mice against a global spectrum of rabies virus variants

Abstract

Rabies, a continuing worldwide problem, kills tens of thousands of people and millions of animals each year.The problem is most severe in developing countries, where cell culture-derived vaccines are unaffordable and the available nervous tissue-derived vaccines are often of questionable immunogenicity and may produce neurological complications. To determine the feasibility of developing a vaccine with worldwide applicability, we investigated whether recombinant vaccinia viruses expressing either the glycoprotein (G), the nucleoprotein (N), or both the G and N (GN) of the challenge virus strain (CVS) of rabies virus would cross-protect mice against 17 rabies virus isolates representing the spectrum of rabies virus variants found worldwide. The results were compared with the commercially available human diploid cell vaccine (HDCV). Among mice injected with any of the 17 viruses, >95% were protected by vaccination with recombinant viruses expressing G or GN, and >85% of the mice were protected by the HDCV. The recombinant virus expressing N was less protective, protecting against only 11 of the 17 viruses. Antibody prepared against the G of the strains used in the vaccines neutralized all 17 viruses, and sera from mice infected with any one virus variant cross-neutralized all of the other viruses. Thus, no antigenic differences that would potentiate vaccine failures were identified. These studies suggest that a single rabies virus strain or its G would protect globally against wild-type rabies viruses.* Corresponding author. Phone: (406) 363-9360. Fax: (406) 363-9204. 4958LODMELL ET AL. J. VIROL.

Epidemiology and biology of a herpesvirus in rabies endemic vampire bat populations

“…Importantly, VBRV and most other bat-associated rabies viruses are maintained in species-specific transmission cycles without alternative hosts that could otherwise compromise vaccination campaigns 37,60 . Moreover, rabies vaccines are broadly protective across Rabies lyssavirus strains and even protect against other lyssaviruses, suggesting that viral antigenic evolution would not be a relevant barrier 61,62 . Finally, decades of experience in vampire bat population control have equipped most Latin American countries with the operational capacity to implement vaccination campaigns alongside or in lieu of culling efforts.…”

Recent Emergence and Spread of an Arctic-Related Phylogenetic Lineage of Rabies Virus in Nepal

“…This vaccine strain had 97% protein sequence similarity to the nucleoprotein of Nepalese viruses in both the Arctic-like and Indian subcontinent clades, whilst the glycoprotein from the vaccine strain had 91–92% similarity to these Nepalese viruses. However cross-protection of isolates belonging to the species RABV in the genus Lyssavirus is quite broad and studies have shown vaccine candidates to elicit protective immunity to many varied rabies strains [45] , [46] .…”

Chimeric Lyssavirus Glycoproteins with Increased Immunological Potential

“…Currently available vaccines mostly belong to GT1, against which they give protection (23). However, the protection against GT4 to GT6 depends on the vaccine strain.…”